Originally published on Technavio:Analysis of the Cancer Biologics Market in North America, Europe, Asia, and Rest of World (ROW) - Including US, Canada, UK, Germany, and China - Size and Forecast 2024-2028

Monoclonal antibodies
The monoclonal antibodies segment is poised for substantial market share growth during the forecast period. These antibodies play a crucial role in targeted therapy or immunotherapy for cancer treatment. By blocking tumor growth through specific targeting, monoclonal antibodies prevent cancer progression or carcinogenesis. These antibodies act on cascade proteins responsible for angiogenesis, altering the way cancer cells divide, repair, grow, and interact with other cells.

Cancer Biologics Market Size

For an overview of the market contribution from various segments, download the PDF Sample.

The monoclonal antibodies segment, valued at USD 51.65 billion in 2018, emerged as the largest segment. Approved monoclonal antibodies in the market include well-known names like Herceptin, Avastin, MabThera/Rituxan, XGEVA, Vectibix, BLINCYTO, OPDIVO, EMPLICITI, YERVOY, LARTRUVO, PORTRAZZA, ERBITUX, CYRAMZA, PERJETA, KADCYLA, TECENTRIQ, GAZYVA, and KEYTRUDA. The segment's growth is fueled by new drug approvals and a robust pipeline of monoclonal antibodies for treatment. Monoclonal antibodies dominate the biologics pipeline, contributing to the segment's growth during the forecast period.

Route Of Administration Analysis 
Injectable
The injectable route of administration is a prevalent and established method for delivering cancer biologics. This approach involves introducing therapeutic agents directly into the bloodstream through intravenous (IV), subcutaneous (SC), or intramuscular (IM) injections. Injectable cancer biologics, often comprising large, complex molecules, demand precise delivery for effective treatment. Several injectable cancer biologics have been developed for various cancers. However, the challenge lies in potential injection site reactions, including redness, swelling, or discomfort, which are closely monitored for patient safety. These factors are expected to contribute to the growth of the injectable segment during the forecast period.
Key Market Players 
Companies are employing various strategies, including strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches to enhance market presence. The report includes detailed analyses of the competitive landscape, featuring information on 20 market companies, such as:

Amgen Inc. - Offering cancer biologics under the brand name Lumakras for KRAS G12C mutated advanced colorectal cancer CRC.

Key Drivers, Trends, Challenges, and Customer Landscape
Market growth is influenced by multiple factors. Researchers analyzed the data, with 2023 as the base year, focusing on key market growth drivers, trends, and challenges.

Key Drivers
The rising global incidence of cancer is a significant driver of market growth. Cancer, a common chronic disease, is becoming a major health concern with increasing global mortality rates. Genetic mutations, environmental factors like tobacco smoking and pollution, and changing dietary patterns contribute to cancer development. The prevalence of these factors directly correlates with the rising global cancer incidence, making cancer the second leading cause of death worldwide. In 2020, there were 19.3 million new cancer cases and 10 million cancer-related deaths globally. The demand for cancer biologics is expected to increase due to the rising incidence of cancer worldwide, driving market growth during the forecast period.

Significant Trends
The untapped potential of cancer biologics in developing countries is an emerging trend influencing market growth. Cancer is a significant health issue in developing countries, where it is turning into a major cause of mortality. Developing countries, including India, China, and Brazil, are gaining attention from global pharmaceutical companies dealing with oncology drugs. Factors such as a large global population and a rising geriatric population drive significant growth in the healthcare sector in developing countries.

To Learn deeper into this report , View Sample PDF

Developing countries, especially in South Asia, heavily rely on chemotherapy drugs for cancer treatment. The increasing prevalence of cancer, combined with the high dependence on chemotherapy drugs, is expected to drive market growth in Asia and other developing regions. These factors shape market growth trends during the forecast period.

For more information please contact.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/